Santhera Pharmaceuticals Holding has completed a 10:1 reverse split of its shares, which had been approved by the shareholders on June 27, 2023, with the listing and first day of trading of the post-split shares on the SIX
Tags :Daniel Häusermann
Homburger has provided legal counsel to Santhera Pharmaceuticals Holding (SIX: SANN “Santhera”) on its completion of a 10:1 reverse split of its shares. The reverse split, which was approved by shareholders on June 27, 2023, resulted in the
Migros has announced a series of steps in its plan to bundle its supermarket business into a centrally managed stand-alone company, Migros Supermarkt. This business represented CHF 12 billion in revenues by 2022. Migros Supermarkt is scheduled
As part of a strategic reorganization, the American cotton manufacturer U.S. Cotton has sold the Flawil-based producer of absorbent cotton and other products, FLAWA Consumer, to members of its management. Homburger advised U.S.
Santhera Pharmaceuticals Holding has announced the grant of an exclusive North America license for the commercialization of vamorolone to Catalyst Pharmaceuticals for a total consideration of up to USD 231 million
Santhera Pharmaceuticals Holding announced a private placement of shares and an amendment of its existing financing with funds managed by Highbridge Capital Management to provide up to CHF 22.2 million in aggregate, subject to certain milestones
ADC Therapeutics, a commercial-stage biotechnology company headquartered in Lausanne, announced the pricing of an underwritten offering of 12 m ADCT shares currently owned by A.T. Holdings II, an affiliate of Auven Therapeutics Holding, at a
StoneX Group, a global financial services company, announced that it had acquired Cotton Distributors (CDI). CDI operates a global cotton merchant business and is headquartered in Lausanne with an office in Brazil. Homburger advised StoneX
MCH Group, a renowed international live marketing company, has announced the result of its rights offering. The company will realise gross proceeds totalling CHF 76.9 million. MCH Group continues to have a stable, long-term anchor shareholder
CDR-Life, a Swiss biotechnology company pioneering a new and differentiated class of highly tumor-specific immune-oncology therapeutics, has completed its Series A financing raising USD 76 million. The round was led by Jeito Capital and RA Capital
